Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HCP2303 vs Co-administered Components in Healthy Volunteers
NCT06357910Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- May 2024
- Primary completion
- Jul 2024
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HCP2303 (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Area Under the Curve from time 0 to last measurable concentration and Maximum Plasma Concentration. Started May 2024; status: completed.
02
Drugs
HCP2303
Beyond the preview
Go deeper on NCT06357910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06357910.